LANSING, Mich., Sept. 26, 2023 /PRNewswire/ -- Neogen Corporation (NASDAQ: NEOG) will issue its first-quarter earnings release before the opening of the market on Tuesday, October 10, 2023. Executives from the company will host a webcast and conference call later that morning, beginning at 8:00 a.m. Eastern time, to discuss the financial results.
The conference call can be accessed by dialing (844) 757-5681 (U.S.) or +1 (412) 317-5297 (international) and requesting the Neogen Corporation First Quarter 2024 Earnings Call (Conference ID: 10182677).
The live webcast can be accessed through Neogen's Investor Relations webpage, neogen.com/investor-relations, under the "Events & Presentations" subheading.
A replay of the conference call and webcast will be available shortly following the conclusion of the call and can be accessed domestically or internationally by dialing (877) 344-7529 or +1 (412) 317-0088, respectively, and providing the passcode 6567809, or through Neogen's Investor Relations website at neogen.com/investor-relations.
About Neogen
Neogen is committed to fueling a brighter future for global food security through the advancement of human and animal well-being. Harnessing the power of science and technology, Neogen Corporation has developed comprehensive solutions spanning the Food Safety, Livestock, and Pet Health & Wellness markets. A world leader in these fields, Neogen has a presence in over 140 countries with a dedicated network of scientists and technical experts focused on delivering optimized products and technology for its customers.
Media Contact
Bill Waelke, Vice President, Investor Relations
517.372.9200 | This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$12.04 |
Daily Change: | 0.02 0.17 |
Daily Volume: | 3,366,036 |
Market Cap: | US$2.610B |
December 17, 2024 October 10, 2024 July 30, 2024 June 27, 2024 |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB